Autologous stem cell transplant for immunoglobulin light chain amyloidosis: A status report

Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne R. Hayman, Shaji K Kumar, David M Dingli, Stephen Maxted Ansell, Dennis A. Gastineau, David J. Inwards, Patrick Bruce Johnston, Mark R Litzow, Ivana Micallef, Luis F. Porrata, Nelson Leung, William Hogan, Francis K. Buadi

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

High-dose chemotherapy for the management of immunoglobulin light chain amyloidosis remains an effective and viable treatment technique for selected patients with this disorder. We reviewed the medical records of 434 patients uniformly treated with high-dose chemotherapy and autologous stem cell transplant at Mayo Clinic, Rochester, Minnesota, between 8 March 1996 and 13 April 2010. Outcomes, engraftment, and predictors of early mortality were reviewed. Median survival has not been reached for the patients with a complete response, is 107 months for those with a partial response, and is 32 months for patients with no response (p<0.001). The only predictor of survival was cardiac stage (p <0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival.

Original languageEnglish (US)
Pages (from-to)2181-2187
Number of pages7
JournalLeukemia and Lymphoma
Volume51
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Immunoglobulin Light Chains
Amyloidosis
Stem Cells
Transplants
Survival
Drug Therapy
Medical Records
Mortality

Keywords

  • Amyloidosis
  • multiple myeloma
  • nephrotic syndrome
  • restrictive cardiomyopathy
  • stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Autologous stem cell transplant for immunoglobulin light chain amyloidosis : A status report. / Gertz, Morie; Lacy, Martha; Dispenzieri, Angela; Hayman, Suzanne R.; Kumar, Shaji K; Dingli, David M; Ansell, Stephen Maxted; Gastineau, Dennis A.; Inwards, David J.; Johnston, Patrick Bruce; Litzow, Mark R; Micallef, Ivana; Porrata, Luis F.; Leung, Nelson; Hogan, William; Buadi, Francis K.

In: Leukemia and Lymphoma, Vol. 51, No. 12, 12.2010, p. 2181-2187.

Research output: Contribution to journalArticle

@article{d13f63dd6f154262a90c0b52aec26b37,
title = "Autologous stem cell transplant for immunoglobulin light chain amyloidosis: A status report",
abstract = "High-dose chemotherapy for the management of immunoglobulin light chain amyloidosis remains an effective and viable treatment technique for selected patients with this disorder. We reviewed the medical records of 434 patients uniformly treated with high-dose chemotherapy and autologous stem cell transplant at Mayo Clinic, Rochester, Minnesota, between 8 March 1996 and 13 April 2010. Outcomes, engraftment, and predictors of early mortality were reviewed. Median survival has not been reached for the patients with a complete response, is 107 months for those with a partial response, and is 32 months for patients with no response (p<0.001). The only predictor of survival was cardiac stage (p <0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival.",
keywords = "Amyloidosis, multiple myeloma, nephrotic syndrome, restrictive cardiomyopathy, stem cell transplant",
author = "Morie Gertz and Martha Lacy and Angela Dispenzieri and Hayman, {Suzanne R.} and Kumar, {Shaji K} and Dingli, {David M} and Ansell, {Stephen Maxted} and Gastineau, {Dennis A.} and Inwards, {David J.} and Johnston, {Patrick Bruce} and Litzow, {Mark R} and Ivana Micallef and Porrata, {Luis F.} and Nelson Leung and William Hogan and Buadi, {Francis K.}",
year = "2010",
month = "12",
doi = "10.3109/10428194.2010.524329",
language = "English (US)",
volume = "51",
pages = "2181--2187",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Autologous stem cell transplant for immunoglobulin light chain amyloidosis

T2 - A status report

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

AU - Kumar, Shaji K

AU - Dingli, David M

AU - Ansell, Stephen Maxted

AU - Gastineau, Dennis A.

AU - Inwards, David J.

AU - Johnston, Patrick Bruce

AU - Litzow, Mark R

AU - Micallef, Ivana

AU - Porrata, Luis F.

AU - Leung, Nelson

AU - Hogan, William

AU - Buadi, Francis K.

PY - 2010/12

Y1 - 2010/12

N2 - High-dose chemotherapy for the management of immunoglobulin light chain amyloidosis remains an effective and viable treatment technique for selected patients with this disorder. We reviewed the medical records of 434 patients uniformly treated with high-dose chemotherapy and autologous stem cell transplant at Mayo Clinic, Rochester, Minnesota, between 8 March 1996 and 13 April 2010. Outcomes, engraftment, and predictors of early mortality were reviewed. Median survival has not been reached for the patients with a complete response, is 107 months for those with a partial response, and is 32 months for patients with no response (p<0.001). The only predictor of survival was cardiac stage (p <0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival.

AB - High-dose chemotherapy for the management of immunoglobulin light chain amyloidosis remains an effective and viable treatment technique for selected patients with this disorder. We reviewed the medical records of 434 patients uniformly treated with high-dose chemotherapy and autologous stem cell transplant at Mayo Clinic, Rochester, Minnesota, between 8 March 1996 and 13 April 2010. Outcomes, engraftment, and predictors of early mortality were reviewed. Median survival has not been reached for the patients with a complete response, is 107 months for those with a partial response, and is 32 months for patients with no response (p<0.001). The only predictor of survival was cardiac stage (p <0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival.

KW - Amyloidosis

KW - multiple myeloma

KW - nephrotic syndrome

KW - restrictive cardiomyopathy

KW - stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=78650073315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650073315&partnerID=8YFLogxK

U2 - 10.3109/10428194.2010.524329

DO - 10.3109/10428194.2010.524329

M3 - Article

C2 - 20958232

AN - SCOPUS:78650073315

VL - 51

SP - 2181

EP - 2187

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -